Sertraline in the Pregabalin: What a Type I Recall Says About Cleaning Validation

On 15 August 2026, Health Canada published a public advisory that should give every Canadian generic manufacturer and contract packer pause. Teva Canada Ltd. is recalling two lots of Teva-Pregabalin 150 mg capsules after the company's own routine testing found that some capsules may be contaminated with sertraline, a completely different prescription active ingredient. Health Canada classified the recall as Type I, its most serious category, and the affected product had been sold in Canada since September 2025.

This is not a nitrosamine trace, an excipient issue or a residual solvent. This is one prescription drug found inside another. For a quality team, that single fact reframes an entire programme, because a second active ingredient does not appear in a finished product by accident. It points to a changeover, cleaning or line-clearance failure that went undetected through release testing for roughly eleven months. The question every reader will ask is simple and uncomfortable: would my cleaning validation have caught this? This article answers it.

Executive summary

Cross-contamination between two different active pharmaceutical ingredients is one of the most serious findings a shared manufacturing facility can produce. The Teva-Pregabalin recall is a live, Canadian example of exactly that risk. Here is what happened, why it matters and what disciplined manufacturers should do now.

What happened: Two lots of Teva-Pregabalin 150 mg capsules (DIN 02361205) were recalled after routine testing detected sertraline, a different active ingredient, in the product. The recall is Type I and national in distribution.
Why it matters: A Type I classification means Health Canada assessed a reasonable probability of serious adverse health consequences. Patients allergic to sertraline could react even at low exposure.
The detection gap: The contamination was found by routine testing, not by batch release testing, roughly eleven months after the product first reached the market. Specifications that do not look for a cross-contaminant will not find one.
What to do: Revisit cleaning validation, changeover controls and line clearance for every shared line, and confirm that quality risk management under ICH Q9(R1) actually drives your acceptance criteria.

What happened: a second drug found inside a prescription product

What is it? Teva Canada recalled two lots of Teva-Pregabalin 150 mg capsules after routine testing identified possible contamination with sertraline. Why does it matter? Sertraline is a separate prescription medicine, so its presence in a pregabalin capsule is a cross-contamination event, not a routine impurity. What should companies do? Treat it as a signal to re-examine shared-equipment controls before an inspector or a customer does.

According to the Health Canada advisory, the recalled capsules carry DIN 02361205 and expire 31 July 2027. Products from the recalled lots were first sold in Canada in September 2025. Health Canada states that it is monitoring the company's recall and the implementation of corrective and preventive actions. Pregabalin treats nerve pain and fibromyalgia. Sertraline treats depression, obsessive-compulsive disorder and panic disorder. A patient with a hypersensitivity or allergy to sertraline could experience side effects or a serious allergic reaction, including anaphylaxis, even at low exposure. That clinical reality is what drives the Type I classification.

Cross-contamination, carryover and mix-up: three terms teams conflate

What is it? These are three distinct failure modes that teams often use interchangeably. Why does it matter? The corrective action for each is different, so mislabelling the event sends the investigation in the wrong direction. What should companies do? Define the event precisely in the deviation, then match the corrective and preventive action to the true mechanism.

Term	What it means	Typical control
Cross-contamination	Unintended presence of one material or product in another, often through shared equipment, air handling or personnel.	Cleaning validation, containment, facility and HVAC design.
Carryover	Residue of a previous product or cleaning agent remaining on equipment and passing into the next batch.	Validated cleaning, health-based limits, verified line clearance.
Mix-up	The wrong material, component or product used or combined in error.	Line clearance, segregation, labelling control, reconciliation.

The Teva event has the hallmarks of a carryover or mix-up at changeover rather than a random environmental cross-contamination, because the contaminant is a specific second active ingredient handled in the same facility. Whichever mechanism the investigation confirms, the control that should have prevented it is the same family: validated cleaning, verified line clearance and disciplined changeover.

Why routine testing caught it and release testing did not

What is it? The contamination surfaced during routine testing, not during batch release. Why does it matter? It means the product passed release and reached patients, and the gap sat undetected for about eleven months. What should companies do? Ask whether the release specification is even capable of detecting the contaminant it should most fear.

Batch release testing confirms a product meets its registered specification. If that specification does not include a method able to detect a cross-contaminating active ingredient, release testing will not find one, and the batch will pass. This is a specification design problem as much as a cleaning problem. Cleaning validation sets and justifies the maximum acceptable carryover of one product into the next, and analytical methods must be sensitive enough to measure residues at those limits. When the two are aligned, a cross-contaminant is caught at source. When they are not, the only backstop is chance, which is what routine testing effectively was here.

The lesson for Canadian manufacturers is that cleaning validation and analytical method validation are a single system. A health-based exposure limit calculated under a quality risk management framework is only as good as the method used to verify it on the equipment surface. Reviewing this link is often the fastest way to close a real gap, and it sits at the centre of MFLRC's pharmaceutical validation work.

Health Canada recall classes: what a Type I really means

What is it? Health Canada assigns every recall a class from Type I to Type III based on the health risk. Why does it matter? Type I is the most serious tier and signals a probable serious hazard. What should companies do? Understand the thresholds so you can anticipate how a regulator will treat a given deviation.

Recall class	What it means	Example trigger
Type I	A reasonable probability that use of, or exposure to, the product will cause serious adverse health consequences or death.	A second active ingredient contaminating a prescription drug, as in the Teva-Pregabalin recall.
Type II	Use of, or exposure to, the product may cause temporary adverse health consequences, or the probability of serious consequences is remote.	A labelling error unlikely to cause lasting harm, or a minor specification failure.
Type III	Use of, or exposure to, the product is not likely to cause any adverse health consequences.	A cosmetic defect or a minor quantity or packaging discrepancy.

The Teva-Pregabalin recall is Type I because a patient allergic to sertraline could suffer a serious reaction. Classification is not about how many units are affected. It is about the probable severity of harm, which is why a two-lot recall of a widely used generic still lands in the most serious category.

What your cleaning validation must prove

What is it? Cleaning validation is documented evidence that a cleaning procedure consistently reduces residues of product, cleaning agents and microbial load to predetermined, health-based limits. Why does it matter? It is the primary control against exactly the event that occurred at Teva. What should companies do? Confirm the programme answers the questions below before, not after, a changeover.

Health-based limits: Are carryover limits derived from a health-based exposure assessment, such as a permitted daily exposure, rather than an outdated 1/1000th of dose rule alone?
Worst-case selection: Have you justified the worst-case product, equipment train and hardest-to-clean location, and does the science still hold as the product mix changes?
Analytical capability: Can the analytical methods actually detect residues at the acceptance limit, and are those methods validated for the surfaces sampled?
Sampling: Do you use both swab and rinse sampling where appropriate, with recovery studies to prove the sampling itself is reliable?
Dedicated versus shared equipment: Have you assessed which products, if any, require dedicated equipment because they cannot be cleaned to a safe limit?
Campaign and changeover limits: Are maximum campaign lengths, dirty and clean hold times and changeover procedures defined and validated?
Line clearance: Is line clearance a verified, documented, independently checked step rather than a signature of convenience?
Revalidation triggers: Do you revalidate cleaning after changes to product, equipment, formulation or cleaning agent, and do you monitor for drift between validations?

A programme that can answer all eight with documented evidence would very likely have prevented, or at least rapidly detected, a cross-contamination event. A programme that cannot is carrying the same risk Teva just made public. A structured validation master plan ties these elements together, and mapping them is a common starting point for a gap assessment.

The regulatory backbone: GUI-0001, Annex 15, ICH Q9 and PIC/S

What is it? Cleaning and changeover controls sit inside a well-defined body of guidance. Why does it matter? Inspectors expect your programme to reflect it, and reliance partners expect the same. What should companies do? Anchor your procedures to the current versions of each document.

In Canada, Health Canada's Good Manufacturing Practices Guide for Drug Products (GUI-0001) sets the expectation that cross-contamination is prevented and that cleaning procedures are validated. EudraLex Volume 4 Annex 15 (Qualification and Validation) describes the lifecycle approach to cleaning validation, including health-based exposure limits. ICH Q9(R1) on Quality Risk Management provides the framework for deciding where dedicated facilities or equipment are warranted and how to set science-based limits. PIC/S PI 006 offers detailed recommendations on validation, including cleaning. Read together, they make one point unmistakable: preventing one product from contaminating another is a designed, evidenced and maintained control, not an assumption.

Cross-contamination control: a compliance checklist

Use this checklist to pressure-test your own facility against the failure mode behind the Teva recall.

Confirm cleaning validation limits are health-based and current for every shared line.
Verify analytical methods can detect each relevant active at the cleaning acceptance limit.
Re-run swab recovery studies for the hardest-to-clean locations.
Document worst-case product and equipment justifications and review them against the current product mix.
Define and validate dirty and clean hold times and maximum campaign lengths.
Make line clearance a witnessed, documented step with a second check.
List any products that require dedicated equipment and record the risk rationale.
Set clear revalidation triggers for product, equipment, formulation and cleaning-agent changes.
Confirm release specifications and stability protocols consider foreseeable cross-contaminants.
Run a mock recall to confirm you can trace and retrieve affected lots quickly.

Common mistakes that lead to cross-contamination

Relying on the historical 1/1000th of a dose limit alone, without a health-based exposure assessment.
Validating cleaning once and never revalidating after a new product joins a shared line.
Using an analytical method that cannot actually detect residues at the acceptance limit.
Treating line clearance as a formality rather than an independently verified control.
Assuming visually clean equals chemically clean without swab or rinse data.
Designing release specifications that test only for expected impurities, never for a plausible cross-contaminant.
Failing to link deviations and complaints to a genuine root-cause and CAPA process, so the same root cause recurs.

Frequently asked questions

What causes one drug to end up inside another drug?

It usually comes from inadequate cleaning between products on shared equipment, a line-clearance failure at changeover, or a mix-up of components or materials. The contaminant is carried over from a previous batch or introduced during a poorly controlled transition. Validated cleaning, verified line clearance and disciplined changeover procedures are the controls designed to prevent it.

What is a Type I recall in Canada?

A Type I recall is Health Canada's most serious classification. It applies where there is a reasonable probability that using or being exposed to the product will cause serious adverse health consequences or death. The Teva-Pregabalin recall is Type I because a patient allergic to sertraline could have a serious reaction, even at low exposure.

Can a company's own routine testing trigger a recall?

Yes. In the Teva case, the company's routine testing, not batch release testing, detected the sertraline contamination and led to the recall. Manufacturers have a duty to act on any credible signal that a product does not meet its quality requirements, regardless of how the signal is found.

How is a cleaning validation acceptance limit set?

Modern practice sets limits using a health-based exposure assessment, such as a permitted daily exposure derived from toxicological data, rather than relying only on the older 1/1000th of the minimum therapeutic dose rule. The limit must then be verified with an analytical method sensitive enough to measure residues at that level on the equipment surface.

How long must cleaning validation and batch records be kept in Canada?

Under Health Canada's GMP framework, records must be retained for defined periods tied to the product's shelf life plus a margin. Because retention periods depend on the product type and licence, confirm the exact requirement in GUI-0001 and your own procedures rather than assuming a single number. The practical point is that records must be complete, contemporaneous and retrievable.

Does visually clean equipment mean it is safe for the next product?

No. Visual inspection is a useful check, but it does not prove that chemical residues are below a health-based limit. That requires swab or rinse sampling, validated analytical methods and recovery studies. Visual assessment supplements, but does not replace, quantitative cleaning verification.

Who is responsible for cleaning validation in a contract manufacturing arrangement?

Accountability is shared and must be defined in a written quality agreement. The contract manufacturer performs and documents the validation, while the marketing authorization holder retains oversight responsibility and must confirm the programme is adequate. Neither party can outsource accountability for product quality.

How MFLRC can help

MFLRC is a Canadian regulatory and quality consultancy with more than twenty years of experience across pharmaceuticals, natural health products, cannabis, food, medical devices and cosmetics. The Teva-Pregabalin recall touches three of our core service areas at once, and we help Canadian manufacturers and contract packers close exactly this kind of gap.

Pharmaceutical validation services: cleaning validation, equipment and process qualification, changeover controls and validation master planning.
Quality assurance services: specification and release-testing review, analytical method coordination and quality management system design.
Audit services: gap assessments, mock recalls, CAPA review and inspection-readiness assessments against Health Canada expectations.

If a second active ingredient turned up in your product tomorrow, would your cleaning validation explain how it got there? We review cleaning validation and changeover controls for Canadian manufacturers and contract packers, and translate the findings into practical corrective actions. Explore our pharmaceutical validation services and quality assurance services, or learn how we support the pharmaceuticals sector.

Book a Consultation

Conclusion

A cross-contamination recall is never really about a single batch. It is about whether the systems that prevent one product from ending up inside another were designed, evidenced and maintained. The Teva-Pregabalin recall is a public reminder that release testing alone is not a safety net, and that cleaning validation, analytical capability and changeover discipline have to work as one. The manufacturers who treat this as a prompt to re-examine their own programmes, rather than someone else's problem, are the ones least likely to appear in next month's advisory. A focused gap assessment and inspection-readiness self-assessment is a straightforward place to start.